Orano Med Advances Collaboration with Roche to Next Phase

Collaboration Announcement: Orano Med and Roche are advancing their collaboration on a novel cancer treatment called "two-step pretargeted radioimmunotherapy" (PRIT), which is now ready for clinical development after successful preclinical research.

Innovative Treatment Approach: The two-step PRIT technique allows for precise targeting of cancer cells by first administering an antibody to the tumor, followed by a radioactive payload, which minimizes radiation exposure to healthy tissues.

Clinical Trial Plans: A phase 1 clinical trial sponsored by Roche is expected to begin in the first half of 2026, focusing on targeting carcinoembryonic antigen (CEA) in various cancers, including colorectal and pancreatic cancers.

Orano Med's Capabilities: Orano Med is responsible for the production and distribution of lead-212 isotopes, leveraging its expertise in nuclear medicine to develop targeted alpha therapies and expand its manufacturing capabilities in North America and Europe.